Greenville, SCNCT07216885Now EnrollingIRB Ready

End Stage Renal Disease Clinical Trial in Greenville, SC

Access cutting-edge end stage renal disease treatment through this clinical trial at a research site in Greenville. Study-provided care at no cost to qualified participants.

Sponsored by Mozarc Medical US LLC

Quick Self-Assessment

See if you qualify for this Greenville location

Preparing your pre-screening questions…

Expert Care in Greenville

Access end stage renal disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related end stage renal disease treatment provided free

Apply for This Greenville Location

Check if you qualify for this end stage renal disease clinical trial in Greenville, SC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Greenville

    Convenient for SC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Greenville site if eligible
  4. 4Begin participation

About This End Stage Renal Disease Study in Greenville

Solv In-Center clinical study is a pre-market, prospective, multicenter, single arm, open-label clinical study. The patient population will include patients with kidney failure or insufficiency requiring hemodialysis and/or ultrafiltration. Eligibility will be open to incident dialysis patients and patients currently receiving HD in an in-center environment. All vascular access types including AV-fistula, AV-graft, and tunneled hemodialysis catheters.

Sponsor: Mozarc Medical US LLC

Who Can Participate

Inclusion Criteria

Subjects able and willing to give Informed Consent and interested to participate in the study
Subject aged 18 years or older
Subjects meets one of the following three conditions:
End stage renal disease (ESRD) patients who have been adequately treated with maintenance HD and deemed stable, according to the investigator, for at least three months
Incident end stage renal disease (ESRD) patients who have been prescribed HD therapy
Subjects on peritoneal dialysis who require conversion to hemodialysis, according to the investigator
Subjects who have adequate access, capable of providing a blood flow rate of at least 300 mL/min
Subject understands the nature of the procedures and the requirements of the study protocol
Subject is willing and able to comply with the protocol requirements and return to the treatment center for all required treatments and clinical evaluations

Exclusion Criteria

Subjects with baseline dry weight of ≤ 60 kg or ≥ 110 kg
Subjects with a documented history of non-compliance to scheduled hemodialysis sessions or clinic visits
Subjects who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to peritoneal dialysis (PD) within the next two months or who require single needle dialysis therapy
Subjects with unstable electrolytes or acid base balance, in the opinion of the investigator
Subjects with any major surgery or major adverse cardiac event within 3 months of screening
Subjects with hemodynamic instability, defined as repeated hypo/hypertension, in the past 30 days from screening
Subjects with active or ongoing infection, in the opinion of the Investigator
Subjects with known Hepatitis B, C or HIV infection
Subject with documented coagulation disorders, active or bleeding risk or who is intolerant to heparin
Subjects who are currently participating or have previously participated in another interventional clinical trial in the past 4 weeks from screening
Subjects with any comorbidities possibly conflicting with the study purpose or procedures, in the opinion of the Investigator
Subjects who are pregnant or lactating or any patient with a childbearing potential who refuses to use medically acceptable means of contraception
Subjects with an active, malignant disease and whose life expectancy is \< 6 months, in the opinion of the investigator
Subjects with a hemoglobin \< 9 gm/dl in the past 30 days from screening
Subjects with significant intradialytic hypotension in 30 days from screening
Subjects with shock within 30 days from screening
Subjects with active seizures in the last 6 months from screening
Subjects with history of hemolytic anemia or thrombocytopenia
Subjects with vascular access dysfunction (switching ports (reverse lines or catheter replacement) in 30 days prior to screening, multiple tPA (tissue plasminogen activator) administrations) or patient who has had a thrombectomy procedure within 30 days prior to screening
Subjects with a documented history of congestive heart failure with symptoms consistent with NYHA Class III or IV, according to the investigator, or documented severe left ventricular dysfunction
Subjects with fluid overload due to intractable ascites secondary to liver cirrhosis
Subjects with active, life-threatening rheumatologic disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Greenville?

Yes, this clinical trial (NCT07216885) has an active research site in Greenville, SC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

End Stage Renal Disease Treatment Options in Greenville, SC

If you're searching for end stage renal disease treatment options in Greenville, SC, this clinical trial (NCT07216885) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Greenville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced end stage renal disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all end stage renal disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Greenville, SC

See all ankylosing spondylitis clinical trials recruiting in Greenville — not just this study.

Browse Ankylosing Spondylitis Trials in Greenville →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsChronic Kidney Disease TrialsAll Conditions →

Ready to Join in Greenville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Greenville, SC